Related Experiment Video

Updated: Mar 3, 2026

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation
09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

12.5K

Thrombopoietin and platelet aggregation in patients with stable coronary artery disease

Sanne Bøjet Larsen1, Erik Lerkevang Grove1,2, Søs Neergaard-Petersen1

  • 1a Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark.

Platelets
|April 25, 2017
PubMed

Insights

Thrombopoietin (TPO) did not significantly impact platelet aggregation or activation in patients with stable coronary artery disease (CAD). This study found only weak associations between TPO levels and platelet aggregation in this patient group.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Platelet Biology

Background:

  • Thrombopoietin (TPO) is implicated in platelet activation and aggregation.
  • Limited data exist on TPO's role in platelet function among patients with stable coronary artery disease (CAD).

Purpose of the Study:

  • To investigate the association between serum TPO levels and platelet aggregation and activation in patients with stable CAD.
  • To identify factors influencing platelet aggregation and TPO levels in this cohort.

Main Methods:

  • Serum TPO levels were measured using ELISA in 900 stable CAD patients.
  • Platelet aggregation was assessed via Multiplate Analyzer (arachidonic acid and collagen agonists) and VerifyNow Aspirin Assay.
  • Platelet activation (sP-selectin) and cyclooxygenase-1 inhibition (serum TXB2) were also evaluated.

Main Results:

  • TPO showed weak correlations with platelet aggregation (Multiplate AA: r = -0.09, p = 0.01; VerifyNow: r = 0.07, p = 0.03) but not with collagen-induced aggregation (r = -0.03, p = 0.43).
  • No significant correlation was observed between TPO and sP-selectin (platelet activation).
  • Independent predictors of platelet aggregation included sP-selectin, serum TXB2, platelet count, age, BMI, female sex, and smoking. Predictors of TPO included low platelet aggregation, hs-CRP, smoking, and high VerifyNow results.

Conclusions:

  • Serum TPO levels demonstrated no substantial association with platelet activation in stable CAD patients.
  • Weak correlations between TPO and platelet aggregation suggest TPO plays a limited role in facilitating platelet aggregation in this population.

Keywords:
AspirinCoronary artery diseasePlatelet activationPlatelet aggregationPlatelet function testsThrombopoietin

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
821
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
347
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
446